Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Stopped early · Phase 1

Conditions studied: Systemic Lupus Erythematosus, Systemic Sclerosis

In brief

The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors) will be well tolerated.

Key facts

Study ID

NCT00684255

Run by

New York Medical College

People needed

1

Starts

2007-08-01

Expected to finish

2008-07-01

Last updated by the study team

2014-04-01

Who can join

Age: 7 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diffuse Systemic Sclerosis and variants as per ACR criteria
• Medically refractory disease
• Adequate Organ Function - Pulmonary function
• Renal function, Cardiac function defined as:
• SGOT (AST) or SGPT (ALT) <5 x upper limit of normal
• Diagnosis of SLE - Medically refractory disease

You may not qualify if…

• Karnofsky/Lansky <60%

Where it is running

• Columbia University Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.